Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Seizures, Epileptic Clear all
Completed No phase listed Observational Results available

Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation

NCT02385526
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Vagus Nerve Stimulation Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

Cenobamate Open-Label Extension Study for YKP3089C025

NCT03961568
View directory record Official record
Conditions
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
La Jolla, California • Miami, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational

Neonatal Seizure Registry - Developmental Functional EValuation

NCT04337697
View directory record Official record
Conditions
Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhages, Epilepsy, Cerebral Palsy, Intellectual Disability
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 8 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
9
States / cities
San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

NCT01142193
View directory record Official record
Conditions
Epilepsy
Interventions
USL255, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational

Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study

NCT03054961
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Near-infrared spectroscopy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
7 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 22, 2026, 3:59 PM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

NCT01465997
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
Not listed
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Alabaster, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Jul 22, 2026, 3:59 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care

NCT06346262
View directory record Official record
Conditions
Epilepsy
Interventions
SMART RM, Valtoco Nasal Product
Behavioral · Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Closed-loop System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy

NCT01415362
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Pediatric CBD Program

NCT02695537
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 19 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

NCT02823145
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 22, 2026, 3:59 PM EDT
Active, not recruiting Phase 4 Interventional

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

NCT06453213
View directory record Official record
Conditions
Focal Onset Seizure
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Women With Epilepsy: Pregnancy Outcomes and Deliveries

NCT01259310
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Great Neck, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Jul 22, 2026, 3:59 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

NCT05128344
View directory record Official record
Conditions
Spasms, Infantile
Interventions
AMZ002 injectable solution, 0.5mg/mL, Vigabatrin, oral
Drug
Lead sponsor
Amzell
Industry
Eligibility
2 Months to 24 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Aurora, Colorado • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

NCT03103425
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Jul 22, 2026, 3:59 PM EDT
Recruiting Not applicable Interventional

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

NCT07445074
View directory record Official record
Conditions
Epilepsy, Seizure
Interventions
Medilepsy® Chatbot AI-Enhanced, Medilepsy® Chatbot Standard
Other
Lead sponsor
University of Central Florida
Other
Eligibility
14 Years to 24 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Results available

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

NCT02724423
View directory record Official record
Conditions
Acute Repetitive Seizures
Interventions
NRL-1
Drug
Lead sponsor
Neurelis, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Results available

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

NCT03116828
View directory record Official record
Conditions
Epilepsy With Partial On-set Seizures
Interventions
Eslicarbazepine Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Mobile, Alabama • Phoenix, Arizona • Downey, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jul 22, 2026, 3:59 PM EDT
Recruiting No phase listed Observational

Investigating Epilepsy: Screening and Evaluation

NCT03478852
View directory record Official record
Conditions
Seizures, Epilepsy, Epilepsy, Temporal Lobe, Partial Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Retraining and Control Therapy (ReACT): Sense of Control and Symptom Expectations as Targets of a Treatment for PNES

NCT05096273
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
ReACT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Not applicable Interventional

Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological Handicaps

NCT01459692
View directory record Official record
Conditions
Seizures, Epilepsy
Interventions
Music Exposure
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 22, 2026, 3:59 PM EDT
Terminated Phase 4 Interventional Results available

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

NCT04650204
View directory record Official record
Conditions
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 22, 2026, 3:59 PM EDT
Recruiting Phase 3 Interventional

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

NCT07563881
View directory record Official record
Conditions
Focal Seizure, Epilepsy, Focal Epilepsy
Interventions
RAP-219, Placebo
Drug · Other
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Palmdale, California • Fort Wayne, Indiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

NCT00524030
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
pregabalin 600 mg/day, pregabalin 150 mg/day
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
63
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 22, 2026, 3:59 PM EDT